



# CERAPEDICS

*Enhancing the Science of Bone Repair*

## **Cerapedics Announces 10,000<sup>th</sup> Patient Treated With i-FACTOR™ Peptide Enhanced Bone Graft**

*Cerapedics achieves significant milestone with its i-FACTOR™ bone grafting platform as a widely accepted treatment option for bony fusion outside the United States*

**WESTMINSTER, Colo. (March 4, 2013)** — Cerapedics, Inc. (Westminster, CO), a medical device company pioneering the use of peptide enhanced bone grafting materials in spine, trauma and orthopedic surgery, is pleased to announce it has surpassed another significant milestone with more than 10,000 patients treated with i-FACTOR™ Peptide Enhanced Bone Graft since the product became available outside the United States in late 2008.

Steve McAdoo, Vice President of Marketing at Cerapedics, stated “this is a significant achievement and milestone for the company and confirms that i-FACTOR bone graft can provide a viable treatment option to both surgeons and patients looking for an alternative to either autograft harvesting or expensive growth factor technologies.”

i-FACTOR Peptide Enhanced Bone Graft incorporates Cerapedics’ proprietary anorganic bone mineral (ABM) and synthetic small peptide (P-15™) technologies for use in a wide variety of spine, trauma and orthopedic surgical procedures. Cerapedics’ i-FACTOR bone graft received CE Mark in late 2008 and has been utilized clinically in over 10,000 spine, trauma and orthopedic surgeries worldwide. Currently, i-FACTOR bone graft is commercially available in both a Putty and Flex (flexible strip) form in more than 20 countries outside the United States. i-FACTOR bone graft is currently being evaluated in the United States (FDA) as part of an Investigational Device Exemption (IDE) Clinical Study in the cervical spine. Cerapedics, Inc. previously announced the company submitted to the FDA the first several modules of its premarket approval application (PMA) for its i-FACTOR bone graft.

### **About Cerapedics, Inc.**

Cerapedics, a 2012 *Colorado Companies to Watch* (COCTW) winner, is a privately-held medical device company focused on developing and commercializing novel osteobiologic products based on its proprietary anorganic bone mineral (ABM) and synthetic small peptide (P-15™) technology platform. i-FACTOR bone graft is the only biologic bone graft that utilizes a small peptide as an attachment factor intended to stimulate the natural bone healing process resulting in safe, predictable bone formation at a fraction of the cost of growth factors.

*CAUTION: i-FACTOR™ bone graft is not commercially available in the USA. In the USA, i-FACTOR bone graft is an investigational device limited by Federal Law (USA) to investigational use only.*

**More information can be found at [www.cerapedics.com](http://www.cerapedics.com).**

Contact:

Steve McAdoo

Vice President of Marketing

Cerapedics, Inc.

+1-303-974-6275

info@cerapedics.com